Evolving treatment strategies for inflammatory bowel disease

Annual Review of Medicine

Volumn 52, Issue , 2001, Pages 299-318

  Hanauer, S B ^a   Dassopoulos, T ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Biologic therapies; Crohn's disease; Infliximab; Ulcerative colitis

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ALICAFORSEN; AMINOSALICYLIC ACID; ANTISENSE OLIGODEOXYNUCLEOTIDE; AZATHIOPRINE; CD 571; CELL ADHESION MOLECULE; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; HEPARIN; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 12; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; MYCOPHENOLIC ACID; NICOTINE GUM; PREDNISOLONE; PROBIOTIC AGENT; RECOMBINANT INTERLEUKIN 11; SALAZOSULFAPYRIDINE; TACROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ANUS DISEASE; CHILL; CLINICAL TRIAL; CROHN DISEASE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; FEVER; GENETIC SUSCEPTIBILITY; HUMAN; IDIOPATHIC DISEASE; ILEITIS; IMMUNE RESPONSE; MAINTENANCE THERAPY; POLYNEUROPATHY; PRIORITY JOURNAL; PRURITUS; REMISSION; REVIEW; SEDATION; ULCERATIVE COLITIS; URTICARIA;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AZATHIOPRINE; CYCLOSPORINS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MESALAMINE; METHOTREXATE; MYCOPHENOLIC ACID; STEROIDS; TACROLIMUS;

EID: 0035127473     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.52.1.299     Document Type: Review

References (143)

1. Homeostasis and self-tolerance in the immune system: Turning lymphocytes off
2. Growth factors in inflammatory bowel disease
3. From immune activation to gut tissue injury: The pieces of the puzzle are coming together
4. Inflammatory bowel disease: Etiology and pathogenesis
5. Ulcerative colitis practice guidelines in adults. American College of Gastroenterology, Practice Parameters Committee
6. Management of Crohn's disease in adults
7. Review articles: Drug therapy: Inflammatory bowel disease
8. Oral 5-aminosalicylic acid for maintaining remission in ulcerative colitis
9. Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis
10. Mesalamine in the maintenance treatment of Crohn's disease: A metaanalysis adjusted for confounding variables
11. Review article: The mode of action of the aminosalicylates in inflammatory bowel disease
12. Sulfasalazine: A potent and specific inhibitor of nuclear factor kappa B
13. Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity
14. Effects of mesalamine on the hsp72 stress response in rat IEC-18 intestinal epithelial cells
15. Review article: Targeted drug delivery in treatment of intestinal diseases
16. Alternatives to sulfasalazine: A metaanalysis of 5-ASA in the treatment of ulcerative colitis
17. Rectal aminosalicylate therapy for distal ulcerative colitis: A meta-analysis
18. Retrograde colonic spread of a new mesalazine rectal enema in patients with distal ulcerative colitis
19. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis
20. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis
21. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: A randomized double-blind study
22. Maintenance treatment of ulcerative proctitis with mesalazine suppositories: A double-blind placebo-controlled trial
23. National Cooperative Crohn's Disease Study: Results of drug treatment
24. European Cooperative Crohn's Disease Study (ECCDS): Results of drug treatment
25. Mesalamine capsules for the treatment of active Crohn's disease: Results of a 16-week trial
26. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis
27. Mesalamine in the treatment of mild to moderate active Crohn's ileitis: Results of a randomized, multicenter trial
28. Mesalamine in Crohn's disease with steroid-induced remission: Effect on steroid withdrawal and remission maintenance
29. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI
30. Anti-inflammatory actions of glucocorticoids: Molecular mechanisms
31. How effective is current medical therapy for severe ulcerative and Crohn's colitis? An analytic review of selected trials
32. Life-threatening complications of IBD: How to handle fulminant colitis and toxic megacolon
33. Rectal corticosteroids versus alternative treatments in ulcerative colitis: A meta-analysis
34. Intensive intravenous treatment of ulcerative colitis
35. Frequency of glucocorticoid resistance and dependency in Crohn's disease
36. Corticosteroids for maintaining remission of Crohn's disease
37. Review article: Drug development in inflammatory bowel disease: Budesonide - A model of targeted therapy
38. A comparison of budesonide with prednisolone for active Crohn's disease
39. Oral budesonide for active Crohn's disease
40. Oral budesonide is as effective as oral prednisolone in active Crohn's disease
41. A comparison of budesonide and mesalamine for active Crohn's disease
42. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study
43. Oral budesonide as maintenance treatment for Crohn's disease: A placebocontrolled, dose-ranging study
44. Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease
45. Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: A multicentre randomized placebo-controlled trial
46. The modern medical management of acute, severe ulcerative colitis
47. Toxic megacolon
48. Medical therapy for induction and maintenance of remission in pouchitis: A systematic review
49. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: The cooperative Crohn's disease study in Sweden. II. Result
50. Double blind, placebo controlled trial of metronidazole in Crohn's disease
51. Metronidazole therapy for perineal Crohn's disease: A follow-up study
52. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection
53. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease
54. Combination ciprofloxacin and metronidazole for active Crohn's disease
55. An antibiotic regimen for the treatment of active Crohn's disease: A randomized, controlled clinical trial of metronidazole plus ciprofloxacin
56. Anti-tuberculous therapy for maintaining remission of Crohn's disease
57. Azathioprine and 6-mercaptopurine in Crohn disease. A metaanalysis
58. A review of immune modifier therapy for inflammatory bowel disease: Azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate
59. Immunotherapy of Crohn's disease
60. Intravenous cyclosporin in ulcerative colitis: A five-year experience
61. Cyclosporin for severe ulcerative colitis: A user's guide
62. Safety of low-dose purine analogues in inflammatory bowel disease
63. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease
64. Azathioprine for maintaining remission of Crohn's disease
65. Postoperative prophylaxis with 6MP, 5-ASA or placebo in Crohn's disease: A 2 year multicenter trial
66. The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease
67. 6-Mercaptopurine metabolism in Crohn's disease: Correlation with efficacy and toxicity
68. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease
69. Methotrexate for inflammatory bowel disease: Pharmacology and preliminary results
70. Methotrexate for the treatment of Crohn's disease
71. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease
72. Methotrexate in chronic active ulcerative colitis: A double-blind, randomized. Israeli multicenter trial
73. Low-dose oral methotrexate in refractory inflammatory bowel disease
74. Mycophenolate mofetil
75. Mycophenolate mofetil in patients with Crohn's disease
76. Treatment of steroid refractory inflammatory bowel disease (IBD) with mycophenolate mofetil (MMF)
77. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease
78. Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn's disease
79. Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease. Part 2: Inflammatory bowel disease, systemic vasculitis, and therapeutic toxicity
80. Preliminary report: Cyclosporin in treatment of severe active ulcerative colitis
81. Cyclosporine in severe ulcerative colitis refractory to steroid therapy
82. Continuously infused cyclosporine at low dose is sufficient to avoid emergency colectomy in acute attacks of ulcerative colitis without the need for high-dose steroids
83. Intravenous cyclosporine for severe attacks of ulcerative colitis: A survey of Canadian gastroenterologists
84. Efficacy of intravenous cyclosporine for steroid refractory attacks of ulcerative colitis
85. Cyclosporine for the treatment of fulminant ulcerative colitis in children. Immediate response, long-term results, and impact on surgery
86. Intravenous cyclosporine in attacks of ulcerative colitis: Short-term and long-term responses
87. Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis
88. Short- and long-term efficacy of cyclosporin administration in patients with acute severe ulcerative colitis
89. A critical review of cyclosporine therapy in inflammatory bowel disease
90. Short-term efficacy and long-term outcome of cyclosporine treatment in patients with severe ulcerative colitis
91. A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin
92. Final report on a placebo-controlled, double-blind, randomised, multicentre trial of cyclosporin treatment in active chronic Crohn's disease
93. Low-dose cyclosporine for the treatment of Crohn's disease
94. Tacrolimus: A further update of its pharmacology and therapeutic use in the management of organ transplantation
95. Oral tacrolimus (FK 506) in Crohn's disease complicated by fistulae of the perineum
96. Steroid-unresponsive acute attacks of inflammatory bowel disease: Immunomodulation by tacrolimus (FK506)
97. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatmentrefractory Crohn's disease perianal fistulae
98. Tumour necrosis factor and Crohn's disease
99. Anticytokine therapy for rheumatoid arthritis
100. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease
101. Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety
102. Infliximab for the treatment of fistulas in patients with Crohn's disease
103. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
104. Review article: Safety of infliximab in clinical trials
105. The relationship between infliximab treatment and lymphoma in Crohn's disease
106. Infliximab in Crohn's disease: First anniversary clinical experience
107. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease
108. A randomized controlled trial of CDP571, a humanized antibody to TNFα in moderately to severely active Crohn's disease
109. A randomized, doubleblind, placebo-controlled, multi-center trial of engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease
110. Immuno-modulation by thalidomide and thalidomide analogues
111. Thalidomide: Current and potential clinical applications
112. New life in a sleeper: Thalidomide and Crolm's disease
113. Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial
114. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease
115. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease
116. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease
117. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease
118. Antibodies to interleukin 12 abrogate established experimental colitis in mice
119. A role for transcription factor NF-kappa B in intestinal inflammation
120. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice
121. Molecules controlling lymphocyte migration to the gut
122. A placebocontrolled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease
123. IBD: A vascular disorder? The case for heparin therapy
124. Heparin, cell adhesion, and pathogenesis of inflammatory bowel disease
125. Paradoxical response to heparin in 10 patients with ulcerative colitis
126. Treatment of corticosteroidresistant ulcerative colitis with heparin a report of 16 cases
127. Low molecular weight heparin as adjuvant therapy in active ulcerative colitis
128. The influence of normal microbial flora on the development of chronic mucosal inflammation
129. Probiotics in inflammatory bowel disease: New insight to pathogenesis or a possible therapeutic alternative?
130. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis
131. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: A randomised trial
132. Maintenance treatment of chronic pouchitis: A randomised placebocontrolled, double-blind trial with a new probiotic preparation
133. Prophylaxis of pouchitis with probiotic therapy: A double-blind, placebo controlled trial
134. Flare-up of Crohn's disease is prevented by Saccharomyces boulardii
135. Inflammatory bowel disease and smoking - A review
136. Testing nicotine gum for ulcerative colitis patients
137. Transdermal nicotine for active ulcerative colitis
138. Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial
139. Transdermal nicotine compared with oral prednisolone therapy for active ulcerative colitis
140. Outcome of ulcerative colitis after treatment with transdermal nicotine
141. Transdermal nicotine as maintenance therapy for ulcerative colitis
142. No butts about it: Put the fire out by lighting up
143. Advances in the management of Crohn's disease: Economic and clinical potential of infliximab